Moberg Pharma AB
MB8
Company Profile
Business description
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company’s main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
Contact
Gustavslundsvagen 42
5th Floor, Bromma
StockholmSE-167 51
SWET: +46 852230700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Chart of the Week: ASX retail offers pockets of value in softening conditions
Why slowing consumer spending could create opportunities in overlooked retail stocks.
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.30 | 129.90 | -1.45% |
| CAC 40 | 7,964.51 | 71.36 | -0.89% |
| DAX 40 | 25,199.19 | 200.02 | -0.79% |
| Dow JONES (US) | 50,906.05 | 443.87 | -0.86% |
| FTSE 100 | 10,606.00 | 30.71 | -0.29% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,861.06 | 63.52 | 0.24% |
| Nikkei 225 | 68,144.29 | 1,390.57 | 2.08% |
| NZX 50 Index | 13,693.74 | 140.65 | -1.02% |
| S&P 500 | 7,651.54 | 19.30 | -0.25% |
| S&P/ASX 200 | 8,659.60 | 129.70 | -1.48% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |